|
項目9：創藥資訊科學－新設立 Final Agenda: Track 9 will explore innovative methods, approaches and technologies that pharmaceutical and biotechnology organizations are utilizing for collaborative drug design, knowledge management and translational medicine. New paradigms in drug discovery will also be addressed.
4月12日(星期二) 7:00 am Workshop Registration and Morning Coffee 8:00 - 4:00 pm Pre-Conference Workshops* *Separate Registration Required. 2:00 - 6:00 Main Conference Registration 4:00 Event Chairperson’s Opening Remarks Cindy Crowninshield, Conference Director, Cambridge Healthtech Institute
5:00 Welcome Reception in the Exhibit Hall and Poster Viewing **Drop off a business card at the CHI Sales booth for a chance to win 1 of 2 iPod®s!
4月13日(星期三) 7:00 am Registration and Morning Coffee 8:15 Event Chairperson’s Opening Remarks Phillips Kuhl, Co-Founder and President, Cambridge Healthtech Institute
9:00 Keynote Presentation & Benjamin Franklin Award
Collaborative Drug Discovery Sponsored by Yuriy Gankin, Ph.D., Co-Founder, CSO, GGA Software Services
Ramesh Durvasula, Ph.D., Director, Chemistry Informatics, Bristol-Myers Squibb, and Board Member, Pistoia Alliance The Pistoia Alliance has been working hard to establish several standards in areas as diverse as e-notebooks, scientific literature, and sequence services. This presentation will provide an update on the progress of Pistoia, and highlight opportunities for attendees to participate in current and emerging standardization efforts. 11:30 Collaborative Virtual Organization & Infrastructure for Anti-Malarial Drug Design Barry Hardy, Ph.D., Project Coordinator, Scientists Against Malaria and SYNERGY The Scientists Against Malaria consortium is a virtual drug discovery organization collaborating on target selection and modeling, protein expression and assay development, computational drug design, and screening. Supported by developments on the EU FP7 funded SYNERGY and OpenTox projects, a combination of interoperable information systems, ontologies and web services were designed and deployed to manage the data, documents, computational and assay results, activity and toxicology predictions, as well as dashboards to track project progress and to support decision making. Sponsored by
Translational Informatics and Knowledge Management 2:10 Chairperson’s Remarks 2:15 The Translational Medicine Ontology: Driving Personalized Medicine by Bridging the Gap from Bedside to Bench Susie Stephens, Ph.D., Director, In Silico Immunology, Centocor Research & Development The Translational Medicine Ontology provides terminology that bridges diverse areas of translational medicine from bedside to bench. An overview of the ontology will be provided along with a demonstration of its utility through question answering over a prototype knowledge base composed of sample patient data integrated with linked open data. Sponsored by Paul Denny-Gouldson, Ph.D., Vice President, Translational Research, IDBS Clinical, ‘omic, CRO and validated data are true capital assets of pharmaceuticals R&D. Agile progression from target to candidate requires the orchestration of diverse scientific disciplines, each generators and consumers of data. Instant access across this entire data landscape is now a must-have capability for speeding innovative products to market. 3:00 Sponsored Presentation (Opportunity Available) 3:15 Refreshment Break in the Exhibit Hall and Poster Viewing 3:45 Driving a Linked Data Framework with Semantic Wikis Laurent Alquier, Ph.D., Project Lead, Pharma R&D Informatics, Johnson & Johnson Pharmaceutical Research & Development Semantic Wikis have matured to become much more than wikis. Recent advances in Semantic MediaWiki make it an ideal, low cost platform for data integration and authoring of Linked Data. A practical example applied to translational research will be provided. 4:00 SEEK and You Will Find … Bo Yang, Senior Manager, Knowledge Management Program, Global Manufacturing Business Technology, Pfizer, Inc. A tremendous amount of experimental information and scientific knowledge has been locked or lost in semi-structured and unstructured data silos in today’s pharmaceutical industry. Enterprise search engines do not understand scientific terms and objects embedded in the contents. This presentation will discuss a scientifically aware search implementation at Pfizer leveraging enterprise search platform. The scope of the document indexing process is expanded to cover embedded chemistry objects and terms such as common chemical names, corporate IDs, SMILES, and InChIs from unstructured content repositories. 4:15 PharmaConnect: Connecting Knowledge from the Lab, Literature and Clinic Bryan Takasaki, Ph.D., IS Informatics Science Director, AstraZeneca The Knowledge Engineering initiative within AstraZeneca has recently delivered the first version of a platform and interface (PharmaConnect) that integrates internal and external evidence for connections between key concepts such as targets, pathways, compounds, diseases and clinical outcome. This talk will describe the impact of this new platform and lessons learned during its development. 4:45 Sponsored Presentation (Opportunity Available) 5:15 Best of Show Awards in the Exhibit Hall 6:15 Exhibit Hall Closes 6:30 – 10:00 Best Practices Awards Reception & Dinner
4月14日(星期四) 8:45 Event Chairperson’s Opening Remarks Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World
Information Sharing Platform 10:55 Chairperson’s Remarks 11:00 How to Turn a Model-T eLabNotebook into a Sleek Tesla Martin D. Leach, Ph.D., Executive Director, IT for Discovery & Pre-Clinical Sciences (DPS), Merck & Co. The prevailing model in large pharmaceutical companies to drive down cost and leverage external innovation is to use COTS software platforms. Without heavy customization, you are at the mercy of the underlying software and database architecture that comes with these products. With increased deployment of our chosen eLabNotebook we hit a performance wall due to the underlying structure of the software. To overcome performance issues we leveraged a third party platform that supercharged the transactional system and transformed this platform into an information sharing environment. Presented by
2:00 Exhibit Hall Closes
New Paradigm in Drug Discovery 1:55 Chairperson’s Remarks 2:00 “Bioactivity Profile” Prediction - From Single to Multiple Targets Using Computational Supporting Methods Andreas Bender, Ph.D., Lecturer for Molecular Informatics, Department of Chemistry, University of Cambridge The prevalent paradigm that drugs should be selective has been changed recently to the ‘selective promiscuity’ approach - that the right combination of targets hit is most promising. In this talk we present proteochemometrics’ methods which consider data from both the ligand and target side to predict bioactivity profiles of compounds across sets of targets. In addition, prospective validations on NNRTI and GPCR datasets will be presented. 2:30 Chemical and Biological Features of Polypharmacology and Promiscuity Florian Nigsch, Ph.D., Presidential Postdoctoral Fellow, Novartis Institutes for BioMedical Research The idiosyncratic use of “polypharmacology” and “promiscuity” incited us to analyze a vast number of compound–protein relations and corresponding target families. A forcefully simplistic model was able to reasonably accurately attribute compounds to either group. Moreover, we analyzed the differences in cellular responses (mRNA levels) to compounds in each group to further delineate the two. 3:00 Identifying Macrocycles as Protein-Protein Inhibitors Using Bioinformatic Analysis of DNA Programmed Chemistry (DPC) Libraries Nathan Walsh, Ph.D., Director, Informatics and IT, Ensemble Therapeutics Corporation This talk will focus on the processing and interpretation of the data generated using DPC libraries of synthetic macrocycle drugs, called Ensemblinstm. Ensemblins, with their unique chemical and biological properties, are a new class of drugs in the emerging therapeutic space between small molecules and biologics. As a therapeutic discovery company we are interested in disease pathways where the targets are considered undruggable with current small molecules. 3:30 The Resurgence of Covalent Drugs and Their Potential as Novel Targeted Therapies Juswinder Singh, Ph.D., Founder and CSO, Avila Therapeutics, Inc. Targeted therapies have revolutionized cancer treatment. Despite this, there is significant need for further chemical and computational innovation to improve potency, selectivity and drug resistance profiles for targeted therapies to make them more effective. This talk will review the potential for computationally designed targeted covalent drugs to overcome these limitations to current therapies. 4:00 Conference Adjourns |
Choose your language
 
  
市場情報資料
產業會議彙總曆
|
